Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

PHASE3CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

October 22, 2015

Primary Completion Date

December 22, 2016

Study Completion Date

December 6, 2018

Conditions
X-linked Hypophosphatemia
Interventions
BIOLOGICAL

burosumab

solution for SC injection

OTHER

Placebo

saline solution for SC injection

Trial Locations (25)

4

St. Vincent's University Hospital, Dublin

21224

Johns Hopkins University, Baltimore

27710

Duke University Medical Center, Durham

43203

The Ohio State University Wexner Medical Center, Columbus

46202

Indiana University Department of Medicine, Indianapolis

50139

Azienda Ospedaliero Universitaria Careggi - Neurofarba, Florence

75010

Hôpital Lariboisière, Dept. of Rheumatology, Paris

75014

CHU Paris Centre-Hôpital Cochin, Paris

77030

Houston Methodist Hospital, Houston

90027

Children's Hospital of Los Angeles, Los Angeles

94158

University of California-San Francisco Medical Center, San Francisco

94275

CHU de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Le Kremlin-Bicêtre

06510

Yale University School of Medicine, New Haven

700-0013

Okayama Saiseikai General Hospital, Okayama

545-8586

Osaka City University Hospital, Osaka

565-0871

Osaka University Hospital, Osaka

105-8470

Toranomon Hospital, Tokyo

113-8655

The University of Tokyo Hospital, Tokyo

110-744

Seoul National University Hospital, Seoul

138-736

Asan Medical Center, Seoul

EH4 2XU

University of Edinburgh Edinburgh Clinical Trials Unit (ECTU) - Western General Hospital, Edinburgh

WC1C 3BG

Univeristy College of London Hospital, London

OX3 7HE

University of Oxford, Oxford

S5 7AU

Northern General Hospital, Metabolic Bone Centre (Sorby Wing), Sheffield

HA7 4LP

Royal National Orthopaedic Hospital, Stanmore

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

lead

Kyowa Kirin, Inc.

INDUSTRY